OVERVIEW

Angiogenesis, Exudation, and Degeneration 2026 – Virtual Edition is organized by Bascom Palmer Eye Institute and will be held on Feb 07, 2026.

Description:
Angiogenesis 2026 follows the tradition of excellence established by Bascom Palmer’s widely acclaimed Angiogenesis programs between 2004 and 2025. Designed for retina specialists, general ophthalmologists, researchers, and industry, the current program will review the latest in imaging, translational research, and clinical trials with an emphasis on how these results will impact clinical ophthalmology. We will emphasize investigator-initiated research and recently completed clinical trials focused on the diagnosis and treatment of a wide range of retinal diseases with special emphasis on age-related macular degeneration, diabetic retinopathy, retinal vascular diseases, and inherited retinal degenerations.

Course Objectives:
Upon completion of this course, participants should be able to:

Understand new evidence for detailing the pathophysiology in nonexudative age-related macular degeneration.
Examine new evidence for predicting disease progression in nonexudative age-related macular degeneration.
Evaluate the benefits and limitations of different imaging and visual function technologies in the diagnosis and clinical management of macular and retinal diseases.
Incorporate the latest advances in artificial intelligence for the diagnosis and management of retinal diseases.
Evaluate emerging therapies for the treatment of late nonexudative age-related macular degeneration and review the real-world outcomes following the use of complement inhibitors in clinical practice to better understand the population most likely to benefit from these drugs.
Evaluate therapies targeting novel disease pathways being investigated in early-stage clinical trials for nonexudative age-related macular degeneration.
Provide an update on anti-VEGF therapies recently approved and currently in development.
Appreciate the next generation of therapies for exudative ocular diseases.
Evaluate emerging therapies for the treatment of inherited retinal degenerations.